Connect with us

The Conversation

When authoritative sources hold onto bad data: A legal scholar explains the need for government databases to retract information

Published

on

When authoritative sources hold onto bad data: A legal scholar explains the need for government databases to retract information

Government information sources like the U.S. patent database often file bad information without labeling it or providing a way to retract it.
Thinglass/iStock via Getty Images

Janet Freilich, Fordham University

In 2004, Hwang Woo-suk was celebrated for his breakthrough discovery creating cloned human embryos, and his work was published in the prestigious journal Science. But the discovery was too good to be true; Dr. Hwang had fabricated the data. Science publicly retracted the article and assembled a team to investigate what went wrong.

Retractions are frequently in the news. The high-profile discovery of a room-temperature superconductor was retracted on Nov. 7, 2023. A series of retractions toppled the president of Stanford University on July 19, 2023. Major early studies on COVID-19 were found to have serious data problems and retracted on June 4, 2020.

Retractions are generally framed as a negative: as science not working properly, as an embarrassment for the institutions involved, or as a flaw in the peer review process. They can be all those things. But they can also be part of a story of science working the right way: finding and correcting errors, and publicly acknowledging when information turns out to be incorrect.

A far more pernicious problem occurs when information is not, and cannot, be retracted. There are many apparently authoritative sources that contain flawed information. Sometimes the flawed information is deliberate, but sometimes it isn’t – after all, to err is human. Often, there is no correction or retraction mechanism, meaning that information known to be wrong remains on the books without any indication of its flaws.

As a patent and intellectual property legal scholar, I’ve found that this is a particularly harmful problem with government information, which is often considered a source of trustworthy data but is prone to error and often lacking any means to retract the information.

Patent fictions and fraud

Consider patents, documents that contain many technical details that can be useful to scientists. There is no way to retract a patent. And patents contain frequent errors: Although patents are reviewed by an expert examiner before being granted, examiners do not check whether the scientific data in the patent is correct.

In fact, the U.S. Patent and Trademark Office permits patentees to include fictional experiments and data in patents. This practice, called prophetic examples, is common; about 25% of life sciences patents contain fictional experiments. The patent office requires that prophetic examples be written in the present or future tense while real experiments can be written in the past tense. But this is confusing to nonspecialists, including scientists, who tend to assume that a phrase like “X and Y are mixed at 300 degrees to achieve a 95% yield rate” indicates a real experiment.

Almost a decade after Science retracted the journal article claiming cloned human cells, Dr. Hwang received a U.S patent on his retracted discovery. Unlike the journal article, this patent has not been retracted. The patent office did not investigate the accuracy of the data – indeed, it granted the patent long after the data’s inaccuracy had been publicly acknowledged – and there is no indication on the face of the patent that it contains information that has been retracted elsewhere.

This is no anomaly. In a similar example, Elizabeth Holmes, the former – now imprisoned – CEO of Theranos, holds patents on her thoroughly discredited claims for a small device that could rapidly run many tests on a small blood sample. Some of those patents were granted long after Theranos’ fraud headlined major newspapers.

A document containing numbers and text
The U.S. Patent and Trademark Office granted a patent to Theranos on Dec. 18, 2018, three months after the company was dissolved following a series of investigations and lawsuits that detailed its fraud. The patent has not been rescinded and contains no notice of the faulty nature of the information it contains.
U.S. Patent and Trademark Office

Long-lived bad information

This sort of under-the-radar wrong data can be deeply misleading to readers. The system of retractions in scientific journals is not without its critics, but it compares favorably to the alternative of no retractions. Without retractions, readers don’t know when they are looking at incorrect information.

My colleague Soomi Kim and I conducted a study of patent-paper pairs. We looked at cases where the same information was published in a journal article and in a patent by the same scientists, and the journal paper had subsequently been retracted. We found that while citations to papers dropped steeply after the paper was retracted, there was no reduction in citations to patents with the very same incorrect information.

This probably happened because scientific journals paint a big red “retracted” notice on retracted articles online, informing the reader that the information is wrong. By contrast, patents have no retraction mechanism, so incorrect information continues to spread.

There are many other instances where authoritative-looking information is known to be wrong. The Environmental Protection Agency publishes emissions data supplied by companies but not reviewed by the agency. Similarly, the Food and Drug Administration disseminates official-looking information about drugs that is generated by drug manufacturers and posted without an evaluation by the FDA.

Retractions play an important role in science.

Consequences of nonretractions

There are also economic consequences when incorrect information can’t be easily corrected. The Food and Drug Administration publishes a list of patents that cover brand-name drugs. The FDA won’t approve a generic drug unless the generic manufacturer has shown that each patent that covers the drug in question is expired, not infringed or invalid.

The problem is that the list of patents is generated by the brand-name drug manufacturers, who have an incentive to list patents that don’t actually cover their drugs. Doing so increases the burden on generic drug manufacturers. The list is not checked by the FDA or anyone else, and there are few mechanisms for anyone other than the brand-name manufacturer to tell the FDA to remove a patent from the list.

Even when retractions are possible, they are effective only when readers pay attention to them. Financial data is sometimes retracted and corrected, but the revisions are not timely. “Markets don’t tend to react to revisions,” Paul Donovan, chief economist of UBS Global Wealth Management, told the Wall Street Journal, referring to governments revising gross domestic product figures.

Misinformation is a growing problem. There are no easy answers to solve it. But there are steps that would almost certainly help. One relatively straightforward one is for trusted data sources like those from the government to follow the lead of scientific journals and create a mechanism to retract erroneous information.The Conversation

Janet Freilich, Associate Professor of Law, Fordham University

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Did you miss our previous article…
https://www.biloxinewsevents.com/?p=313935

The Conversation

The Vera C. Rubin Observatory will help astronomers investigate dark matter, continuing the legacy of its pioneering namesake

Published

on

theconversation.com – Samantha Thompson, Astronomy Curator, National Air and Space Museum, Smithsonian Institution – 2025-06-24 07:35:00


Everything visible in space, including stars and planets, accounts for only about 15% of the universe’s matter; the rest is dark matter, which is invisible but detectable through its gravitational effects. The Vera C. Rubin Observatory, starting its 10-year mission with the largest digital camera ever built, will capture detailed images of billions of galaxies to study dark matter’s role in the universe’s structure. Vera Rubin’s pioneering work in the 1960s revealed stars in galaxies move faster than visible matter predicts, suggesting unseen mass. Her legacy continues as astronomers use data to explore dark matter’s mysteries.

The Rubin Observatory is scheduled to release its first images in 2025.
RubinObs/NOIRLab/SLAC/NSF/DOE/AURA/B. Quint

Samantha Thompson, Smithsonian Institution

Everything in space – from the Earth and Sun to black holes – accounts for just 15% of all matter in the universe. The rest of the cosmos seems to be made of an invisible material astronomers call dark matter.

Astronomers know dark matter exists because its gravity affects other things, such as light. But understanding what dark matter is remains an active area of research.

With the release of its first images this month, the Vera C. Rubin Observatory has begun a 10-year mission to help unravel the mystery of dark matter. The observatory will continue the legacy of its namesake, a trailblazing astronomer who advanced our understanding of the other 85% of the universe.

As a historian of astronomy, I’ve studied how Vera Rubin’s contributions have shaped astrophysics. The observatory’s name is fitting, given that its data will soon provide scientists with a way to build on her work and shed more light on dark matter.

Wide view of the universe

From its vantage point in the Chilean Andes mountains, the Rubin Observatory will document everything visible in the southern sky. Every three nights, the observatory and its 3,200 megapixel camera will make a record of the sky.

This camera, about the size of a small car, is the largest digital camera ever built. Images will capture an area of the sky roughly 45 times the size of the full Moon. With a big camera with a wide field of view, Rubin will produce about five petabytes of data every year. That’s roughly 5,000 years’ worth of MP3 songs.

After weeks, months and years of observations, astronomers will have a time-lapse record revealing anything that explodes, flashes or moves – such as supernovas, variable stars or asteroids. They’ll also have the largest survey of galaxies ever made. These galactic views are key to investigating dark matter.

Galaxies are the key

Deep field images from the Hubble Space Telescope, the James Webb Space Telescope and others have visually revealed the abundance of galaxies in the universe. These images are taken with a long exposure time to collect the most light, so that even very faint objects show up.

Researchers now know that those galaxies aren’t randomly distributed. Gravity and dark matter pull and guide them into a structure that resembles a spider’s web or a tub of bubbles. The Rubin Observatory will expand upon these previous galactic surveys, increasing the precision of the data and capturing billions more galaxies.

In addition to helping structure galaxies throughout the universe, dark matter also distorts the appearance of galaxies through an effect referred to as gravitational lensing.

Light travels through space in a straight line − unless it gets close to something massive. Gravity bends light’s path, which distorts the way we see it. This gravitational lensing effect provides clues that could help astronomers locate dark matter. The stronger the gravity, the bigger the bend in light’s path.

Many galaxies, represented as bright dots, some blurred, against a dark background.
The white galaxies seen here are bound in a cluster. The gravity from the galaxies and the dark matter bends the light from the more distant galaxies, creating contorted and magnified images of them.
NASA, ESA, CSA and STScI

Discovering dark matter

For centuries, astronomers tracked and measured the motion of planets in the solar system. They found that all the planets followed the path predicted by Newton’s laws of motion, except for Uranus. Astronomers and mathematicians reasoned that if Newton’s laws are true, there must be some missing matter – another massive object – out there tugging on Uranus. From this hypothesis, they discovered Neptune, confirming Newton’s laws.

With the ability to see fainter objects in the 1930s, astronomers began tracking the motions of galaxies.

California Institute of Technology astronomer Fritz Zwicky coined the term dark matter in 1933, after observing galaxies in the Coma Cluster. He calculated the mass of the galaxies based on their speeds, which did not match their mass based on the number of stars he observed.

He suspected that the cluster could contain an invisible, missing matter that kept the galaxies from flying apart. But for several decades he lacked enough observational evidence to support his theory.

A woman adjusting a large piece of equipment.
Vera Rubin operates the Carnegie spectrograph at Kitt Peak National Observatory in Tucson.
Carnegie Institution for Science, CC BY

Enter Vera Rubin

In 1965, Vera Rubin became the first women hired onto the scientific staff at the Carnegie Institution’s Department of Terrestrial Magnetism in Washington, D.C.

She worked with Kent Ford, who had built an extremely sensitive spectrograph and was looking to apply it to a scientific research project. Rubin and Ford used the spectrograph to measure how fast stars orbit around the center of their galaxies.

In the solar system, where most of the mass is within the Sun at the center, the closest planet, Mercury, moves faster than the farthest planet, Neptune.

“We had expected that as stars got farther and farther from the center of their galaxy, they would orbit slower and slower,” Rubin said in 1992.

What they found in galaxies surprised them. Stars far from the galaxy’s center were moving just as fast as stars closer in.

“And that really leads to only two possibilities,” Rubin explained. “Either Newton’s laws don’t hold, and physicists and astronomers are woefully afraid of that … (or) stars are responding to the gravitational field of matter which we don’t see.”

Data piled up as Rubin created plot after plot. Her colleagues didn’t doubt her observations, but the interpretation remained a debate. Many people were reluctant to accept that dark matter was necessary to account for the findings in Rubin’s data.

Rubin continued studying galaxies, measuring how fast stars moved within them. She wasn’t interested in investigating dark matter itself, but she carried on with documenting its effects on the motion of galaxies.

A quarter with a woman looking upwards engraved onto it.
A U.S quarter honors Vera Rubin’s contributions to our understanding of dark matter.
United States Mint, CC BY

Vera Rubin’s legacy

Today, more people are aware of Rubin’s observations and contributions to our understanding of dark matter. In 2019, a congressional bill was introduced to rename the former Large Synoptic Survey Telescope to the Vera C. Rubin Observatory. In June 2025, the U.S. Mint released a quarter featuring Vera Rubin.

Rubin continued to accumulate data about the motions of galaxies throughout her career. Others picked up where she left off and have helped advance dark matter research over the past 50 years.

In the 1970s, physicist James Peebles and astronomers Jeremiah Ostriker and Amos Yahil created computer simulations of individual galaxies. They concluded, similarly to Zwicky, that there was not enough visible matter in galaxies to keep them from flying apart.

They suggested that whatever dark matter is − be it cold stars, black holes or some unknown particle − there could be as much as 10 times the amount of dark matter than ordinary matter in galaxies.

Throughout its 10-year run, the Rubin Observatory should give even more researchers the opportunity to add to our understanding of dark matter.The Conversation

Samantha Thompson, Astronomy Curator, National Air and Space Museum, Smithsonian Institution

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Read More

The post The Vera C. Rubin Observatory will help astronomers investigate dark matter, continuing the legacy of its pioneering namesake appeared first on theconversation.com



Note: The following A.I. based commentary is not part of the original article, reproduced above, but is offered in the hopes that it will promote greater media literacy and critical thinking, by making any potential bias more visible to the reader –Staff Editor.

Political Bias Rating: Centrist

The content is focused entirely on scientific topics related to astronomy, dark matter, and the legacy of astronomer Vera Rubin without engaging in political rhetoric or ideological framing. Its tone is neutral, educational, and fact-based, presenting information grounded in scientific research and historical context. As such, it does not lean toward any particular political bias but maintains an objective, centrist stance typical of purely scientific communication.

Continue Reading

The Conversation

3 years after abortion rights were overturned, contraception access is at risk

Published

on

theconversation.com – Cynthia H. Chuang, Professor of Medicine and Public Health Sciences, Penn State – 2025-06-23 07:39:00


On June 24, 2022, the U.S. Supreme Court’s Dobbs v. Jackson Women’s Health Organization decision overturned Roe v. Wade, ending federal abortion rights and shifting regulation to states. Since then, many states have imposed severe abortion restrictions, increasing demand for effective contraception like IUDs and sterilization. However, the decision has also led to diminished access to contraception due to abortion clinic closures, decreased healthcare provider availability, and threats to insurance coverage. Efforts to wrongly classify some contraceptives as abortifacients risk limiting coverage under Medicaid and the Affordable Care Act, endangering contraception access amid rising need.

Women living in states that ban or severely restrict abortion may be especially motivated to avoid unintended pregnancy.
Viktoriya Skorikova/Moment via Getty Images

Cynthia H. Chuang, Penn State and Carol S. Weisman, Penn State

On June 24, 2022, the U.S. Supreme Court decision in Dobbs v. Jackson Women’s Health Organization eliminated a nearly 50-year constitutional right to abortion and returned the authority to regulate abortion to the states.

The Dobbs ruling, which overturned Roe v. Wade, has vastly reshaped the national abortion landscape. Three years on, many states have severely restricted access to abortion care. But the decision has also had a less well-recognized outcome: It is increasingly jeopardizing access to contraception.

We are a physician scientist and a sociologist and health services researcher studying women’s health care and policy, including access to contraception. We see a worrisome situation emerging.

Even while the growing limits on abortion in the U.S. heighten the need for effective contraception, family planning providers are less available in many states, and health insurance coverage of some of the most effective types of contraception is at risk.

A growing demand for contraception

Abortion restrictions have proliferated around the country since the Dobbs decision. As of June 2025, 12 states have near-total abortion bans and 10 states ban abortion before 23 or 24 weeks of gestation, which is when a fetus is generally deemed viable. Of the remaining states, 19 restrict abortion after viability and nine states and Washington have no gestational limits.

It’s no surprise that women living in states that ban or severely restrict abortion may be especially motivated to avoid unintended pregnancy. Even planned pregnancies have grown riskier, with health care providers fearing legal repercussions for treating pregnancy-related medical emergencies such as miscarriages. Such concerns may in part explain emerging research that suggests the use of long-acting contraception such as intrauterine devices, or IUDs, and permanent contraception – namely, sterilization – are on the rise.

A national survey conducted in 2024 asked women ages 18 to 49 if they have changed their contraception practices “as a result of the Supreme Court overturning Roe v. Wade.” It found that close to 1 in 5 women began using contraception for the first time, switched to a more effective contraceptive method, received a sterilization procedure or purchased emergency contraception to keep on hand.

The Supreme Court’s decision in Dobbs reshaped the landscape of abortion access across the U.S.

A study in Ohio hospitals found a nearly 16% increase in women choosing long-acting contraception methods or sterilization in the six months after the Dobbs decision, and a 33% jump in men receiving vasectomies. Another study, which looked at both female and male sterilization in academic medical centers across the country, also reported an uptick in sterilization procedures for young adults ages 18 to 30 after the Dobbs decision, through 2023.

A loss of contraception providers

Ironically, banning or severely restricting abortion statewide may also diminish capacity to provide contraception.

To date, there is no compelling evidence that OB-GYN doctors are leaving states with strict abortion laws in significant numbers. One study found that states with severe abortion restrictions saw a 4.2% decrease in such practitioners compared with states without abortion restrictions.

However, the Association of American Medical Colleges reports declining applications to residency training programs located in states that have abortion bans – not just for OB-GYN training programs, but for residency training of all specialties. This drop suggests that doctors may be overall less likely to train in states that restrict medical practice. And given that physicians often stay on to practice in the states where they do their training, it may point to a long-term decline in physicians in those states.

But the most significant drop in contraceptive services likely comes from the closure of abortion clinics in states with the most restrictive abortion policies. That’s because such clinics generally provide a wide range of reproductive services, including contraception. The 12 states with near-total abortion bans had 57 abortion clinics in 2020, all of which were closed as of March 2024. One study reported a 4.1% decline in oral contraceptives dispensed in those states.

Contraception under threat

The Dobbs decision has also encouraged ongoing efforts to incorrectly redefine some of the most effective contraceptives as medications that cause abortion. These efforts target emergency contraceptive pills, known as Plan B over-the-counter and Ella by prescription, as well as certain IUDs. Emergency contraceptive pills are up to 98% effective at preventing pregnancy after unprotected sex, and IUDs are 99% effective.

Neither method terminates a pregnancy, which by definition begins when a fertilized egg implants in the uterus. Instead, emergency contraceptive pills prevent an egg from being released from the ovaries, while IUDs, depending on the type, prevent sperm from fertilizing an egg or prevent an egg from implanting in the uterus.

Conflating contraception and abortion spreads misinformation and causes confusion. People who believe that certain types of contraception cause abortions may be dissuaded from using those methods and rely on less effective methods. What’s more, it may affect health insurance coverage.

Medicaid, which provides health insurance for low-income children and adults, has been required to cover family planning services at no cost to patients since 1972. Since 2012, the Affordable Care Act has required private health insurers to cover certain women’s health preventive services at no cost to patients, including the full-range of contraceptives approved by the Food and Drug Administration.

According to our research, the insurance coverage required by the Affordable Care Act has increased use of IUDs, which can be prohibitively expensive when paid out of pocket. But if IUDs and emergency contraceptive pills were reclassified as interventions that induce abortion, they likely would not be covered by Medicaid or the Affordable Care Act, since neither type of health insurance requires coverage for abortion care. Thus, access to some of the most effective contraceptive methods could be jeopardized at a time when the right to terminate an unintended or nonviable pregnancy has been rolled back in much of the country.

Indeed, Project 2025, the conservative policy agenda that the Trump administration appears to be following, specifically calls for removing Ella from the Affordable Care Act contraception coverage mandate because it is a “potential abortifacient.” And politicians in multiple states have expressed support for the idea of restricting these contraceptive methods, as well as contraception more broadly.

On the third anniversary of the Dobbs decision, it is clear that its ripple effects include threats to contraception. Considering that contraception use is almost universal among women in their reproductive years, in our view these threats should be taken seriously.The Conversation

Cynthia H. Chuang, Professor of Medicine and Public Health Sciences, Penn State and Carol S. Weisman, Distinguished Professor Emerita of Public Health Sciences, Penn State

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Read More

The post 3 years after abortion rights were overturned, contraception access is at risk appeared first on theconversation.com



Note: The following A.I. based commentary is not part of the original article, reproduced above, but is offered in the hopes that it will promote greater media literacy and critical thinking, by making any potential bias more visible to the reader –Staff Editor.

Political Bias Rating: Center-Left

This article presents a viewpoint consistent with Center-Left perspectives by emphasizing the negative impacts of the Dobbs decision on abortion and contraception access. It highlights concerns about reduced reproductive rights, healthcare provider shortages, and efforts to restrict or redefine contraception, portraying these developments as threats to women’s health. The language frames the Dobbs ruling and related policies critically, focusing on public health consequences and policy setbacks, which aligns with progressive and moderate Democratic-leaning concerns. While it is evidence-based and cites research, the framing and selection of issues suggest a bias toward protecting reproductive rights and opposing restrictive abortion policies.

Continue Reading

The Conversation

Neuropathic pain has no immediate cause – research on a brain receptor may help stop this hard-to-treat condition

Published

on

theconversation.com – Pooja Shree Chettiar, Ph.D. Candidate in Medical Sciences, Texas A&M University – 2025-06-23 07:38:00


Neuropathic pain arises from nervous system dysfunction, causing persistent, unexplained pain and altering brain function, leading to emotional distress. Affecting about 10% of the U.S. population, it creates major health and economic burdens, often treated inadequately. Neuroscientists study molecules reshaping pain perception, focusing on the GluD1 receptor, a protein organizing synapses crucial for pain circuits. GluD1 disrupts in chronic pain, destabilizing synaptic communication and amplifying pain signals. Reactivating GluD1 with cerebellin-1 in mouse studies restored synaptic function and reduced pain without opioid side effects. While early, this research suggests a promising approach to treating neuropathic pain by repairing neural networks rather than masking symptoms.

Neuropathic pain is experienced both physically and emotionally.
Salim Hanzaz/iStock via Getty Images

Pooja Shree Chettiar, Texas A&M University and Siddhesh Sabnis, Texas A&M University

Pain is easy to understand until it isn’t. A stubbed toe or sprained ankle hurts, but it makes sense because the cause is clear and the pain fades as you heal.

But what if the pain didn’t go away? What if even a breeze felt like fire, or your leg burned for no reason at all? When pain lingers without a clear cause, that’s neuropathic pain.

We are neuroscientists who study how pain circuits in the brain and spinal cord change over time. Our work focuses on the molecules that quietly reshape how pain is felt and remembered.

We didn’t fully grasp how different neuropathic pain was from injury-related pain until we began working in a lab studying it. Patients spoke of a phantom pain that haunted them daily – unseen, unexplained and life-altering.

These conversations shifted our focus from symptoms to mechanisms. What causes this ghost pain to persist, and how can we intervene at the molecular level to change it?

More than just physical pain

Neuropathic pain stems from damage to or dysfunction in the nervous system itself. The system that was meant to detect pain becomes the source of it, like a fire alarm going off without a fire. Even a soft touch or breeze can feel unbearable.

Neuropathic pain doesn’t just affect the body – it also alters the brain. Chronic pain of this nature often leads to depression, anxiety, social isolation and a deep sense of helplessness. It can make even the most routine tasks feel unbearable.

About 10% of the U.S. population – tens of millions of people – experience neuropathic pain, and cases are rising as the population ages. Complications from diabetes, cancer treatments or spinal cord injuries can lead to this condition. Despite its prevalence, doctors often overlook neuropathic pain because its underlying biology is poorly understood.

Person lying on side in bed, eyes closed, possibly grimacing
Neuropathic pain can be debilitating.
Kate Wieser/Moment via Getty Images

There’s also an economic cost to neuropathic pain. This condition contributes to billions of dollars in health care spending, missed workdays and lost productivity. In the search for relief, many turn to opioids, a path that, as seen from the opioid epidemic, can carry its own devastating consequences through addiction.

GluD1: A quiet but crucial player

Finding treatments for neuropathic pain requires answering several questions. Why does the nervous system misfire in this way? What exactly causes it to rewire in ways that increase pain sensitivity or create phantom sensations? And most urgently: Is there a way to reset the system?

This is where our lab’s work and the story of a receptor called GluD1 comes in. Short for glutamate delta-1 receptor, this protein doesn’t usually make headlines. Scientists have long considered GluD1 a biochemical curiosity, part of the glutamate receptor family, but not known to function like its relatives that typically transmit electrical signals in the brain.

Instead, GluD1 plays a different role. It helps organize synapses, the junctions where neurons connect. Think of it as a construction foreman: It doesn’t send messages itself, but directs where connections form and how strong they become.

This organizing role is critical in shaping the way neural circuits develop and adapt, especially in regions involved in pain and emotion. Our lab’s research suggests that GluD1 acts as a molecular architect of pain circuits, particularly in conditions like neuropathic pain where those circuits misfire or rewire abnormally. In parts of the nervous system crucial for pain processing like the spinal cord and amygdala, GluD1 may shape how people experience pain physically and emotionally.

Fixing the misfire

Across our work, we found that disruptions to GluD1 activity is linked to persistent pain. Restoring GluD1 activity can reduce pain. The question is, how exactly does GluD1 reshape the pain experience?

In our first study, we discovered that GluD1 doesn’t operate solo. It teams up with a protein called cerebellin-1 to form a structure that maintains constant communication between brain cells. This structure, called a trans-synaptic bridge, can be compared to a strong handshake between two neurons. It makes sure that pain signals are appropriately processed and filtered.

But in chronic pain, the bridge between these proteins becomes unstable and starts to fall apart. The result is chaotic. Like a group chat where everyone is talking at once and nobody can be heard clearly, neurons start to misfire and overreact. This synaptic noise turns up the brain’s pain sensitivity, both physically and emotionally. It suggests that GluD1 isn’t just managing pain signals, but also may be shaping how those signals feel.

What if we could restore that broken connection?

Resembling paint splatter, a round glob of green, yellow and red is superimposed on each other and surrounded by flecks of these same colors
This image highlights the presence of GluD1, in green and yellow, in a neuron of the central amygdala, in red.
Pooja Shree Chettiar and Siddhesh Sabnis/Dravid Lab at Texas A&M University, CC BY-SA

In our second study, we injected mice with cerebellin-1 and saw that it reactivated GluD1 activity, easing their chronic pain without producing any side effects. It helped the pain processing system work again without the sedative effects or disruptions to other nerve signals that are common with opioids. Rather than just numbing the body, reactivating GluD1 activity recalibrated how the brain processes pain.

Of course, this research is still in the early stages, far from clinical trials. But the implications are exciting: GluD1 may offer a way to repair the pain processing network itself, with fewer side effects and less risk of addiction than current treatments.

For millions living with chronic pain, this small, peculiar receptor may open the door to a new kind of relief: one that heals the system, not just masks its symptoms.The Conversation

Pooja Shree Chettiar, Ph.D. Candidate in Medical Sciences, Texas A&M University and Siddhesh Sabnis, Ph.D. Student in Medical Sciences, Texas A&M University

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Read More

The post Neuropathic pain has no immediate cause – research on a brain receptor may help stop this hard-to-treat condition appeared first on theconversation.com



Note: The following A.I. based commentary is not part of the original article, reproduced above, but is offered in the hopes that it will promote greater media literacy and critical thinking, by making any potential bias more visible to the reader –Staff Editor.

Political Bias Rating: Centrist

This article presents a neutral and factual overview of neuropathic pain and related scientific research. It focuses on explaining medical concepts, recent findings, and potential treatments without expressing any political opinions or ideological stances. The language is technical and objective, aiming to inform rather than persuade or advocate for any political position. The content neither promotes nor criticizes specific policies or political actors, maintaining a clear focus on science and health. Therefore, the article aligns with centrist, unbiased reporting.

Continue Reading

Trending